Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
News|Articles|June 1, 2015
Teva Launches Generic Version of Actonel
Author(s)Pharmaceutical Technology Editors
Teva announces the exclusive launch of its generic equivalent of Actonel in the US.
Advertisement
On June 1, 2015, Teva Pharmaceutical launched the generic version of Actavis’ Actonel (risedronate sodium) for the treatment and prevention of osteoporosis in post-menopausal women. The tablets, which come in 5, 30, and 35 mgs, were launched in the US with 180 days of market exclusivity, as Teva was the first to file for the generic version.
The drug helps to increase bone mass and reduce the risk of bone fractures, can help to treat and prevent osteoporosis in both men and women who are taking corticosteroids, and can help to treat Paget’s disease of the bone, according to a press release. The new generic marks the second osteoporosis treatment in Teva’s portfolio.
Source:
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement